169 related articles for article (PubMed ID: 38727420)
1. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials.
Peixoto VP; Prudêncio C; Vieira M
Curr Med Res Opin; 2024 May; ():1-11. PubMed ID: 38727420
[TBL] [Abstract][Full Text] [Related]
2. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
3. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
Wong RSM
Ther Adv Hematol; 2022; 13():20406207221114673. PubMed ID: 35923770
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough Hemolysis Associated With COVID-19 Vaccination and Active COVID-19 Infection in a Patient With Paroxysmal Nocturnal Hemoglobinuria Maintained on Pegcetacoplan: A Case Report.
Boshkos MC; Fives KR; Phrathep DD; Healey KD; Patel M
Cureus; 2023 Mar; 15(3):e36240. PubMed ID: 37065335
[TBL] [Abstract][Full Text] [Related]
6. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lee JW; Griffin M; Kim JS; Lee Lee LW; Piatek C; Nishimura JI; Carrillo Infante C; Jain D; Liu P; Filippov G; Sicre de Fontbrune F; Risitano A; Kulasekararaj AG;
Lancet Haematol; 2023 Dec; 10(12):e955-e965. PubMed ID: 38030318
[TBL] [Abstract][Full Text] [Related]
7. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
Heo YA
Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
[TBL] [Abstract][Full Text] [Related]
8. Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.
Xu B; Kang B; Chen J; Li S; Zhou J
Blood Rev; 2024 Jul; 66():101210. PubMed ID: 38811284
[TBL] [Abstract][Full Text] [Related]
9. Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
Xu B
Clin Exp Med; 2023 Jul; 23(3):717-726. PubMed ID: 35441351
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
Kulasekararaj AG; Risitano AM; Maciejewski JP; Notaro R; Browett P; Lee JW; Huang M; Geffner M; Brodsky RA
Blood; 2021 Nov; 138(20):1928-1938. PubMed ID: 34314483
[TBL] [Abstract][Full Text] [Related]
11. Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
Di Matteo S; Freilone R; Bruno GM; Notaro R; Moumene S; Martone N; Teruzzi C; Ciccarone A; Colombo GL
Clinicoecon Outcomes Res; 2024; 16():225-232. PubMed ID: 38623087
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Wong RSM; Pullon HWH; Amine I; Bogdanovic A; Deschatelets P; Francois CG; Ignatova K; Issaragrisil S; Niparuck P; Numbenjapon T; Roman E; Sathar J; Xu R; Al-Adhami M; Tan L; Tse E; Grossi FV
Ann Hematol; 2022 Sep; 101(9):1971-1986. PubMed ID: 35869170
[TBL] [Abstract][Full Text] [Related]
13. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.
Risitano AM; Peffault de Latour R; Marano L; Frieri C
Semin Immunol; 2022 Jan; 59():101618. PubMed ID: 35764467
[TBL] [Abstract][Full Text] [Related]
14. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria.
Frieri C; Peffault de Latour R; Sicre De Fontbrune F
Expert Opin Emerg Drugs; 2022 Mar; 27(1):33-43. PubMed ID: 35078384
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.
Kulasekararaj AG; Kuter DJ; Griffin M; Weitz IC; Röth A
Blood Rev; 2023 May; 59():101041. PubMed ID: 36732204
[TBL] [Abstract][Full Text] [Related]
19. The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria.
Kulasekararaj AG; Brodsky RA; Nishimura JI; Patriquin CJ; Schrezenmeier H
Ther Adv Hematol; 2022; 13():20406207221091046. PubMed ID: 35663504
[TBL] [Abstract][Full Text] [Related]
20. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
